Cytodyn Inc (CYDY)

[$5.95akadawson-m]

Let's review a part of today's shareholder letter - for those who have a hard time understanding it, I will help with the explanation:

Over the next six months, we expect to commence at least one, and potentially two clinical trials. The prospective clinical trials, in order of priority, are: (i) a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer; and (ii) a Phase II study exploring leronlimab’s effects on inflammation. The Company’s priority will be the oncology trial which, if successful, will put us on track towards a commercial approval of leronlimab in that indication.

This sentence: "The Company’s priority will be the oncology trial which, if successful, will put us on track towards a commercial approval of leronlimab in that indication."

"Put us on track towards a commercial approval...." This "indication" is an unmet need, today. An unmet need means that no one has been able to successfully treat colorectal cancer! And, it's a Phase II. The gravy train starts after the completion of the Phase II. All aboard, Grip It!